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659Abstracts
The average cost of management per patient over the 
10-month period of this group was HKD85,324
(USD$10,940, HKD7.8 = USD$1). Hospitalisation rep-
resented the major cost item (64.6%), followed by cost
of investigational tests (14.5%) and procedural cost
(11.6%). The average cost per patient in the hypothetical
cohort was HKD83,903 (USD$10,757). CONCLUSION:
According to our analytical model, the overall cost impact
between clopidogrel plus aspirin vs aspirin alone in the 2
groups of patients was similar.
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OBJECTIVES: The isosmolar contrast medium (CM)
iodixanol has been shown to reduce the risk of major
adverse cardiac events and have a higher intervention
success rate compared with the low-osmolar agent
ioxaglate in patients undergoing PCI at high risk of com-
plications. The purpose of this study was to assess to what
extent this clinical beneﬁt is associated with differences in
health care costs for PCI patients in France and Spain.
METHODS: A decision tree model was developed to
compare the costs associated with receiving each CM in
high-risk and low-risk patients. Clinical data were derived
from published comparative clinical trials. Data on
medical resource use associated with managing adverse
events were obtained from panels of French and Spanish
interventional cardiologists, and resource use was con-
verted to costs using nationally representative country-
speciﬁc tariffs. The study end-point was the difference
between CM groups in the cost of treatment during the
hospitalization period for a patient undergoing PCI. Uni-
variate sensitivity analyses were performed to test the
robustness of the results. RESULTS: In France, the direct
cost of treatment per high-risk patient for iodixanol was
€231 lower than for ioxaglate. The direct cost of treat-
ment per low-risk patient was €45 higher for iodixanol
than for ioxaglate. In Spain, the direct cost of treatment
for iodixanol compared with ioxaglate was €220 lower
per high-risk patient and correspondingly €92 higher per
low-risk patient. CONCLUSIONS: This study suggests
that in high-risk patients undergoing PCI, the use of
iodixanol confers an economic beneﬁt as well as a clini-
cal beneﬁt in each study country. For low-risk patients a
converse economic beneﬁt is seen. When considering all
patients these results suggest that the use of iodixanol
confers an economic beneﬁt if the proportion of high-risk
patients exceeds 30% in Spain and 17% in France.
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OBJECTIVES: To evaluate the inpatient and outpatient
maintenance costs associated with treatment for acute
myocardial infarction in the Greek NHS. METHODS: A
database from a large NHS University Hospital was
employed and analyzed. Resource consumption data were
combined with 2003 price data to compute overall treat-
ment costs. Inpatient costs of an uncomplicated AMI
comprise all costs associated with treating an event in-
hospital and these include the costs of wards, PTCAs,
medications, cardiac ICU, etc. The marginal costs of
having one of many types of events, such as strokes, re-
infarction, etc, are also computed. The outpatient main-
tenance costs of patients include medication taken after
the AMI for certain period or life-time, visits to profes-
sionals and rehabilitation in cases of events such as
strokes. RESULTS: The costs of initial inpatient medica-
tion given is between €790 and €1000. The average cost
of hospitalization is about €8.474 and the additional cost
per event is as follows: stroke—€1300, bleeding—€90,
reinfraction—€1125, recurrent ischemia: 0, CHF—€561,
hypotention: 0, cardiogenic chock—€1.730, electro-
mechanical dissociation—€121, tamponate or cardiac
rapture—€279, second degree atrioventicular block—
€961, third degree atrioventicular block: €1.521, artial
ﬁbrillation: €100, asystole: €121, acute mitral requirgita-
tion—€1.415, septal defect: €415, anaphylaxis:€300, 
pulmonary embolism: €2.050, arrythmias: €100, hypo-
tention: €0, pericarditis—€100. The cost of rehabilitation
and maintenance is on average €915 in the ﬁrst year plus
€4.5 per day after discharge and during lifetime thereafter.
Severe stroke is associated with an extra of €1.000 in the
ﬁrst year. CONCLUSION: AMI is an expensive to treat
event. The cost of initial medication given is low in com-
parison with the total treatment cost within the hospital
and after discharge. The associated events are also very
expensive to treat and multiply total cost. Any reduction
therefore in MI’s, given the high prevalence, will save the
NHS and the taxpayer a lot of money.
